chemoprophylaxis for tuberculosis

From Aaushi
Jump to navigation Jump to search

Management

More general terms

Additional terms

References

  1. Manual of Medical Therapeutics, 28th ed, Ewald & McKenzie (eds), Little, Brown & Co, Boston, 1995
  2. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 183-86
  3. American Thoracic Society: Am J Crit Care Med 149:1359-1374 1994
  4. 4.0 4.1 4.2 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 19. American College of Physicians, Philadelphia 1998, 2006, 2021.
  5. Prescriber's Letter 7(7):40 2000
  6. Kaiser Permanente, Northern California, Infection Control Update, 9/2000
  7. 7.0 7.1 7.2 Journal Watch 21(19):155, 2001 MMWR Morb Mort Wkly Rep 50:733, 2001
  8. 8.0 8.1 Prescriber's Letter 10(9):50 2003
  9. 9.0 9.1 9.2 Lardizabal A et al, Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006, 130:1712 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17166986
    Ashkin D et al, Consider rifampin BUT be cautious Chest 2006, 130:1638 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17166975
  10. American Thoracic Society, Targeted Testing and Treatment of Latent Tuberculosis Infection, Am J Respir Crit Care Med 161:S221, 2000 http://www.atsjournals.org
  11. 11.0 11.1 CDC Press Release May 16m 2011 Session B9, oral presentation: Sterling, PREVENT TB: Results of a 12-Dose, Once-Weekly Treatment of Latent Tuberculosis Infection (LTBI) http://www.cdc.gov/nchhstp/newsroom/PREVENTTBPressRelease.html
    Sterling TR et al Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection N Engl J Med 2011; 365:2155-2166 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22150035 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1104875
    Dye C Practical Preventive Therapy for Tuberculosis? N Engl J Med 2011; 365:2230-2231 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22150042 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1111859
    Centers for Disease Control and Prevention Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection MMWR. December 9, 2011 / 60(48);1650-1653 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm
    Prescriber's Letter 19(2): 2012 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280210&pb=PRL (subscription needed) http://www.prescribersletter.com
  12. 12.0 12.1 12.2 Anger HA et al. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Clin Infect Dis 2012 May 1; 54:1287 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22412056
  13. 13.0 13.1 Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011 Dec 9;60(48):1650-3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22157884
  14. Centers for Disease Control and Prevention Treatment for Latent TB Infection http://www.cdc.gov/tb/topic/treatment/ltbi.htm